Hospira UK Ltd Queensway, Royal Leamington Spa, Warwickshire
Total Page：16
File Type：pdf, Size：1020Kb
Hospira UK Ltd Queensway, Royal Leamington Spa, Warwickshire, CV31 3RW Telephone: +44 (0)1926 820 820 Fax: +44 (0) 1926 834446 WWW: http://www.hospira.com Medical Information Direct Line: +44 (0) 1926 834400 Medical Information e-mail: [email protected] Customer Care direct line: +44 (0)1926 821 022 Need to contact this company? Summary of Product Characteristics last updated on the eMC: 07/05/2009 Vincristine Sulphate 1mg/ml Injection (5mg/5ml) (Hospira UK Ltd) 1. NAME OF THE MEDICINAL PRODUCT Vincristine Sulphate 1 mg/ml Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml contains 1.0 mg of vincristine sulphate Each 5ml presentation contains 5 mg of vincristine sulphate For excipients, see 6.1 3. PHARMACEUTICAL FORM Solution for injection A sterile, colourless solution 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of: 1. Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia 2. Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas. 3. Multiple myeloma. 4. Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas. 5. Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma. 6. Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses. 4.2 Posology and method of administration This preparation is for intravenous use only. It should only be administered by individuals experienced in vincristine administration. FOR INTRAVENOUS USE ONLY FATAL IF GIVEN BY ANY OTHER ROUTE See Section 4.4 Special warnings and precautions for use. Vincristine sulphate is administered by intravenous injection at weekly intervals, the precise dose being determined by body weight. Great care should be exercised in calculating the dose as overdosage may be extremely serious or even fatal. The dose should not be increased beyond the level which produces therapeutic benefit. In general, individual doses should not exceed 2mg; and white cell counts should be carried out before and after giving each dose. Vincristine Sulphate Injection may be injected into the tubing or side arm of a free-flowing intravenous infusion or directly into a vein over a one-minute period. For safety reasons when administering Vincristine Sulphate Injection into a side arm of a fast running infusion, please ensure that pressure is maintained on the syringe plunger during administration, to avoid back pressure from the infusion forcing the plunger out of the syringe barrel. Care should be taken to avoid extravasation as this may cause local ulceration. The following dosage regimens have been used: Adults: The drug is usually administered intravenously at weekly intervals. The recommended dose is 1.4 to 1.5 mg/m2 up to a maximum weekly dose of 2 mg. Children: The suggested dose is 1.4 to 2 mg/m2 given on a weekly basis with a maximum weekly dose of 2 mg. For children weighing 10 kg or less the starting dose should be 0.05 mg/kg administered as a weekly intravenous injection. Elderly: The normal adult dose is still appropriate in the elderly. Hepatic Impairment: Because of the hepatic metabolism and biliary excretion of vincristine, reduced doses are recommended in patients with obstructive jaundice or other hepatic impairment. Patients with liver disease sufficient to decrease biliary excretion may experience an increase in the severity of side-effects. A 50 per cent reduction in the dose of vincristine sulphate is recommended for patients having a direct serum bilirubin value above 3 mg/100 ml (51 micromol/l). Caution: If leakage into surrounding tissue should occur during intravenous administration of vincristine, it may cause considerable irritation. The injection should be discontinued immediately and any remaining portion of the dose should then be introduced into another vein. Local injection of the hyaluronidase and the application of moderate heat to the area of leakage help to disperse the drug and are thought to minimise discomfort and the possibility of cellulitis. 4.3 Contraindications Intrathecal administration of vincristine sulphate is usually fatal. Patients with the demyelinating form of Charcot-Marie-Tooth syndrome should not be given vincristine. As Vincristine Sulphate Injection contains benzyl alcohol it must not be given to premature babies or neonates. Vincristine Sulphate Injection should not be given to patients who have shown signs of hypersensitivity to vincristine or to any of the excipients Careful notice should also be given to those conditions listed in Section 4.4 Special warnings and precautions for use. 4.4 Special warnings and precautions for use Warnings This preparation is for intravenous use only. It should be administered by physicians experienced in the administration of vincristine sulphate. Vincristine sulphate should not be given by intrathecal, intramuscular or subcutaneous injection. The intrathecal administration of vincristine sulphate usually results in death. Syringes containing this product should be labelled 'VINCRISTINE FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN BY OTHER ROUTES' . After inadvertent intrathecal administration, immediate neurosurgical intervention is required in order to prevent ascending paralysis leading to death. In a very small number of patients, life- threatening paralysis and subsequent death was averted but resulted in devastating neurological sequelae, with limited recovery afterwards. Based on the published management of these survival cases, if vincristine is mistakenly given by the intrathecal route, the following treatment should be initiated immediately after the injection: 1. Removal of as much CSF as is safely possible through the lumbar access. 2. Insertion of an epidural catheter into the subarachnoid space via the intervertebral space above initial lumbar access and CSF irrigation with lactated Ringer's solution. Fresh frozen plasma should be requested and, when available, 25 ml should be added to every 1 litre of lactated Ringer's solution. 3. Insertion of an intraventricular drain or catheter by a neurosurgeon and continuation of CSF irrigation with fluid removal through the lumbar access connected to a closed drainage system. Lactated Ringer's solution should be given by continuous infusion at 150 ml/h, or at a rate of 75 ml/h when fresh frozen plasma has been added as above. The rate of infusion should be adjusted to maintain a spinal fluid protein level of 150 mg/dl. The following measures have also been used in addition but may not be essential: Folinic acid has been administered intravenously as a 100 mg bolus and then infused at a rate of 25 mg/h for 24 hours, then bolus doses of 25 mg 6-hourly for 1 week. Intravenous administration of glutamic acid 10 g over 24 hours, followed by 500 mg three times daily by mouth for one month. Pyridoxine has been given at a dose of 50 mg 8 hourly by intravenous infusion over 30 minutes. Their roles in the reduction of neurotoxicity are unclear. Vincristine sulphate is a vesicant and may cause severe local reaction or extravasation, see Caution in Section 4.2, Posology and Method of Administration. As Vincristine Sulphate Injection contains benzyl alcohol it may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old. Precautions Leucopenia is less likely following therapy with vincristine sulphate than is the case with other oncolytic agents. It is usually neuromuscular rather than bone marrow toxicity that limits dosage. However, because of the possibility of leucopenia, both physician and patient should remain alert for signs of any complicating infection. If leucopenia or a complicating infection is present, then administration of the next dose of vincristine sulphate warrants careful consideration. Acute uric acid nephropathy, which may occur after administration of oncolytic agents, has also been reported with vincristine sulphate. As vincristine sulphate penetrates the blood-brain barrier poorly, additional agents and routes of administration may be required for central nervous system leukaemias. The neurotoxic effect of vincristine sulphate may be additive with other neurotoxic agents or increased by spinal cord irradiation and neurological disease. Elderly patients may be more susceptible to the neurotoxic effects of vincristine sulphate. Both in vivo and in vitro laboratory tests have failed to demonstrate conclusively that this product is mutagenic. Fertility following treatment with vincristine alone for malignant disease has not been studied in humans. Clinical reports of both male and female patients who received multiple- agent chemotherapy that included vincristine indicate that azoospermia and amenorrhoea can occur in postpubertal patients. Recovery occurred many months after completion of chemotherapy in some but not all patients. When the same treatment is administered